Noesis Capital Mangement Corp Purchases New Holdings in OraSure Technologies, Inc. (OSUR)

Noesis Capital Mangement Corp bought a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,000 shares of the medical instruments supplier’s stock, valued at approximately $225,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Federated Investors Inc. PA lifted its stake in OraSure Technologies by 505.6% in the second quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock valued at $5,395,000 after acquiring an additional 260,977 shares during the last quarter. Chicago Equity Partners LLC lifted its stake in OraSure Technologies by 38.3% in the second quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock valued at $1,354,000 after acquiring an additional 21,730 shares during the last quarter. USA Financial Portformulas Corp lifted its stake in OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 13,421 shares during the last quarter. Eqis Capital Management Inc. acquired a new stake in OraSure Technologies in the second quarter valued at approximately $371,000. Finally, 361 Capital LLC lifted its stake in OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 10,107 shares during the last quarter. Hedge funds and other institutional investors own 92.93% of the company’s stock.

A number of brokerages have recently weighed in on OSUR. BidaskClub cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Canaccord Genuity boosted their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Wednesday, September 20th. ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Jefferies Group LLC cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $18.21.

Shares of OraSure Technologies, Inc. (OSUR) traded down $0.28 during trading on Wednesday, hitting $14.11. 743,600 shares of the stock were exchanged, compared to its average volume of 871,482. OraSure Technologies, Inc. has a twelve month low of $8.01 and a twelve month high of $23.01. The firm has a market capitalization of $872.73, a PE ratio of 27.67, a price-to-earnings-growth ratio of 2.76 and a beta of 1.39.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.09. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business had revenue of $42.30 million during the quarter, compared to analysts’ expectations of $40.87 million. During the same period in the previous year, the company earned $0.11 earnings per share. OraSure Technologies’s revenue for the quarter was up 31.0% on a year-over-year basis. equities research analysts anticipate that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Noesis Capital Mangement Corp Purchases New Holdings in OraSure Technologies, Inc. (OSUR)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/11/15/noesis-capital-mangement-corp-purchases-new-holdings-in-orasure-technologies-inc-osur.html.

In related news, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $23.00, for a total transaction of $527,229.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mara G. Aspinall bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The shares were bought at an average cost of $14.23 per share, for a total transaction of $71,150.00. Following the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The disclosure for this purchase can be found here. Insiders have sold 61,110 shares of company stock worth $1,362,463 in the last ninety days. 6.40% of the stock is currently owned by insiders.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply